Kalytera is working to create a new class of CBD drugs with increased bioavailability to deliver more effective doses to patients. They are doing this through research on two fronts.
The first front focuses on further research into the use of CBD. Combining what is already an impressive body of research on the substance with a more in-depth clinical analysis, Kalytera hopes “to expedite regulatory approval and commercialization.” Their CBD research includes several programs that study the efficacy of CBD in bone health and healing for patients with Osteoporosis, bone fractures, Osteogenesis imperfecta, and Prader-Willi Syndrome (PWS).
The second front involves developing and creating synthetic cannabinoids with better bioavailability to deliver more efficient doses.
Kalytera’s research programs study the use of CBD in conjunction with these synthetic cannabinoids in treating patients.
In the 1960’s, Dr. Raphael Mechoulam, an Israeli researcher, was one of the first to successfully identify THC and CBD, the main components of marijuana. His research led him to petition the Israeli Ministry of Health to approve medical marijuana in 1992 and establish a program for researchers and patients, a move which has positioned Israel at the forefront of medical marijuana research.
